Research & Publications +
Dr. Holdhoff's research is focused on translational research projects and clinical trials in neuro-oncology. As a member of the Brain Cancer Program and the Ludwig Center for Cancer Genetics and Therapeutics at Johns Hopkins, he heads a working group for the development of blood-based biomarkers in malignant gliomas. Dr. Holdhoff graduated from medical school at Freie Universitt Berlin and he received his doctorate degree (German PhD equivalent) at Charit University Medicine Berlin. After internal medicine training at Johns Hopkins Bayview Medical Center he completed his medical oncology fellowship and subspecialty training in neuro-oncology at the Sidney Kimmel Comprehensive Cancer Center. Dr. Holdhoff is board certified in internal medicine and medical oncology and he has a clinic for patients with primary brain tumors, CNS lymphomas and other malignancies of the central nervous system.
Holdhoff M, Supko JG, Gallia GL, Hann CL, Bonekamp D, Ye X, Cao B, Olivi A, Grossman SA. Intratumoral concentrations of imatinib after oral administration in patients with glioblastoma multiforme. J. Neurooncol 2010; 97: 241-5 (Epub ahead of print Sept 19, 2009).
Holdhoff M, Schmidt K, Donehower R, Diaz LA, Jr. Analysis of Circulating Tumor DNA to Confirm Somatic KRAS Mutations. J Natl Cancer Inst 2009; 101: 1284-5.
Holdhoff M, Parsons DW, Diaz LA, Jr. Mutations of IDH1 and IDH2 are not detected in brain metastases of colorectal cancer. J Neurooncol 2009; 94: 297 (Epub ahead of print April 7).
Holdhoff M, Wung PK, Petronis JD, Couzi R. Persistent positron emission tomography-positive liver lesions after successful chemotherapy in mediastinal seminoma. J Clin Oncol. 2007; 25: 2482-4.
Holdhoff M, Kreuzer KA, Appelt C, Scholz R, Na IK, Hildebrandt B, Riess H, Jordan A, Schmidt CA, Van Etten RA, Drken B, le Coutre P. Radiosensitization of a human glioblastoma cell line by imatinib mesylate through inhibition of platelet-derived growth factor receptor. Blood Cells Mol Dis 2005; 34: 181-185.
le Coutre P, Kreuzer KA, Na IK, Schwarz M, Lupberger J, Holdhoff M, Baskaynak G, Gschaidmeier H, Platzbecker U, Ehninger G, Prejzner W, Huhn D, Schmidt CA: Imatinib in Philadelphia chromosome positive chronic phase CML patients: molecular and cytogenetic response rates and prediction of clinical outcome. Am J Hematol 2003; 73: 249-255.
le Coutre P, Kreuzer KA, Na IK, Lupberger J, Holdhoff M, Appelt, C, Schwarz M, Mller C, Gambacorti-Passerini C, Platzbecker U, Bonnet R, Ehninger G, Schmidt CA: Determination of alpha-1 acid glycoprotein in patients with Ph+ chronic myeloid leukaemia during the first 13 weeks of therapy with STI571. Blood Cells Mol Dis 2002; 28: 75-85.